248 related articles for article (PubMed ID: 12625594)
1. Matrix metalloproteinases and coronary artery diseases.
Ikeda U; Shimada K
Clin Cardiol; 2003 Feb; 26(2):55-9. PubMed ID: 12625594
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and atherosclerosis.
Watanabe N; Ikeda U
Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease.
Bench TJ; Jeremias A; Brown DL
Pharmacol Res; 2011 Dec; 64(6):561-6. PubMed ID: 21624471
[TBL] [Abstract][Full Text] [Related]
4. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
George SJ
Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
8. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty.
Hojo Y; Ikeda U; Katsuki Ta; Mizuno O; Fujikawa H; Shimada K
Atherosclerosis; 2002 Mar; 161(1):185-92. PubMed ID: 11882331
[TBL] [Abstract][Full Text] [Related]
10. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.
Fukuda D; Shimada K; Tanaka A; Kusuyama T; Yamashita H; Ehara S; Nakamura Y; Kawarabayashi T; Iida H; Yoshiyama M; Yoshikawa J
Am J Cardiol; 2006 Jan; 97(2):175-80. PubMed ID: 16442358
[TBL] [Abstract][Full Text] [Related]
11. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
Wang W; Zhang HT; Yang XL
J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability.
Xie S; Nie R; Wang J
J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879
[TBL] [Abstract][Full Text] [Related]
13. [Pathophysiological bases of unstable coronary syndrome].
Waltenberger J
Herz; 2001 Apr; 26 Suppl 1():2-8. PubMed ID: 11349622
[TBL] [Abstract][Full Text] [Related]
14. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
Ruddy JM; Ikonomidis JS; Jones JA
J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases: a therapeutic target in cardiovascular disease.
Sierevogel MJ; Pasterkamp G; de Kleijn DP; Strauss BH
Curr Pharm Des; 2003; 9(13):1033-40. PubMed ID: 12678855
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
Johnson JL
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
[TBL] [Abstract][Full Text] [Related]
17. [Matrix metalloproteinase-1 and coronary atheroslerotic plaque rupture].
Guo A; Wei L; Shi H; Li X; You L
Zhonghua Bing Li Xue Za Zhi; 2000 Aug; 29(4):263-6. PubMed ID: 11866921
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
Rouis M
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
[TBL] [Abstract][Full Text] [Related]
19. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling.
Schoenhagen P; Vince DG; Ziada KM; Kapadia SR; Lauer MA; Crowe TD; Nissen SE; Tuzcu EM
Am J Cardiol; 2002 Jun; 89(12):1354-9. PubMed ID: 12062727
[TBL] [Abstract][Full Text] [Related]
20. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
Olejarz W; Łacheta D; Kubiak-Tomaszewska G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
